Streetwise Expert Interviews

Clinton's Price Caps Are a Non-Starter: Liana Moussatos of Wedbush Securities

This fall, presidential candidate Hillary Clinton once again proposed price caps on out-of-pocket payments for pharmaceuticals. Liana Moussatos of Wedbush Securities has followed the price-cap discussion since the 1990s, and says the issue is more political than real. Given that, she tells The Life Sciences Report about some up-and-coming companies with products she believes are likely to make big improvements in the health of patients and the wallets of investors.

(11/24/15) More >
Read More Streetwise Interviews

Oppenheimer's Rohit Vanjani: Finding Profit in the Generic Drug Pricing Wars

Oppenheimer & Co.'s Rohit Vanjani sees clear ways to profit from generic drug companies despite recent political blowups, and identifies a handful of select generic drug and specialty pharma stocks that still have pricing power and margin expansion potential. (11/18/15) More >

Newsletter Briefs

"MSB is planning an IPO in the U.S. under the symbol MESO and is now reporting in U.S. dollars." (10/30/15) Mesoblast Ltd. - Henry McCusker, RegMed Investors More >

"CANF's CF602 candidate showed a significant improvement in penile erection relative to placebo." (10/22/15) Can-Fite BioPharma Ltd. - Jennifer Poland, BioTuesdays More >

"We find RESX to be a worthwhile investment." (10/28/15) RestorGenex Corp. - The Life Sciences Report Interview with Jay Albany More >

"CYP's lead medical technology platform has very exciting potential." (10/28/15) Cynata Therapeutics Ltd. - The Life Sciences Report Interview with Jay Albany More >

"We've seen a lot of acceleration for AEMD since the Hemopurifier was used successfully to treat an Ebola patient in Germany." (10/28/15) Aethlon Medical Inc. - The Life Sciences Report Interview with Jay Albany More >

"STEM is a pioneering company dealing with the challenges of cell therapies." (10/7/15) StemCells Inc. - The Life Science Report Interview with Bernie Siegel More >

"SNSS is significantly undervalued." (9/30/15) Sunesis Pharmaceuticals Inc. - The Life Sciences Report Interview with Hartaj Singh More >

"INO has a very broad pipeline that seems to be moving steadily." (9/23/15) Inovio Pharmaceuticals Inc. - The Life Sciences Report Interview with Jason McCarthy More >

Expert Analysis

"Data show CANF's CF102 has activity in an animal model of NASH." (11/24/15) Can-Fite BioPharma Ltd. - Mark Breidenbach, H.C. Wainwright & Co. More >

"MSB's Phase 2 study in rheumatoid arthritis is enrolling 48 patients." (11/24/15) Mesoblast Ltd. - Kevin DeGeeter, Ladenburg Thalmann More >

"IMUC showed a survival benefit for ICT-107 in defined subgroups." (11/22/15) ImmunoCellular Therapeutics Ltd. - Joseph Pantginis, ROTH Capital Partners More >

"The FDA cleared the clinical trial of INO's MERS vaccine, GLS-5300." (11/20/15) Inovio Pharmaceuticals Inc. - Yi Chen, H.C. Wainwright & Co. More >

"ATHX's MAPC improved the health of rodents after acute SCI." (11/19/15) Athersys Inc. - Henry McCusker, RegMed Investors More >

"BCLI is ideally positioned to capture interest." (11/17/15) BrainStorm Cell Therapeutics Inc. - Jason McCarthy, Maxim Group More >

"RGS achieved an important business milestone for the Progenza osteoarthritis therapy." (11/12/15) Regeneus Ltd. - Proactive Investors More >

"ATHX data suggest MultiStem could be used for severe SCI patients." (11/18/15) Athersys Inc. - Jason Kolbert, Maxim Group More >